Absci
ABSI
Market cap $379M

2.78 USD

-0.06

2.11%

At close Jun 13, 4:00 PM EDT

After hours

2.80

+0.02

0.72%

1 day

-2.11%

5 days

-9.45%

1 month

-6.08%

3 months

-4.14%

6 months

-24.86%

Year to date

2.58%

1 year

-36.38%

5 years

-87.12%

10 years

-87.12%

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Employees: 157

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

46% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 24

45% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 33

11% more capital invested

Capital invested by funds: $194M [Q4 2024] → $215M (+$21.1M) [Q1 2025]

6% more funds holding

Funds holding: 132 [Q4 2024] → 140 (+8) [Q1 2025]

2.84% more ownership

Funds ownership: 64.33% [Q4 2024] → 67.17% (+2.84%) [Q1 2025]

19% less call options, than puts

Call options by funds: $1.58M | Put options by funds: $1.94M

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

152%

upside

Avg. target

$8.75

215%

upside

High target

$10

260%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Needham Gil Blum	224%upside $9	Buy Reiterated	14 May 2025
Keybanc Scott Schoenhaus	224%upside $9	Overweight Maintained	16 Apr 2025
Guggenheim Vamil Divan	260%upside $10	Buy Reiterated	20 Mar 2025
HC Wainwright & Co. Swayampakula Ramakanth	152%upside $7	Buy Reiterated	19 Mar 2025

See Analyst Rankings

Financial journalist opinion

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will be participating in the following upcoming investor conferences.

Absci to Participate in Upcoming Investor Conferences

Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript

Absci Corporation (NASDAQ:ABSI ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and Chief Executive Officer Zach Jonasson - Chief Financial Officer and Chief Business Officer Christian Stegmann - Senior Vice President of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Securities Brendan Smith - TD Cowen Gil Blum - Needham & Company George Farmer - Scotiabank Debanjana Chatterjee - Jones Li Chen - H.C. Wainwright Operator Thank you for standing by, and welcome to Absci's First Quarter 2025 Business Update and Financial and Operating Results Conference Call.

Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.22 per share a year ago.

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the quarter ended March 31, 2025.

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and convenience over first-generation anti-TL1As Interim data anticipated in the second half of 2025 VANCOUVER, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in a randomized, placebo-controlled Phase 1 study evaluating ABS-101, an investigational anti-TL1A antibody engineered with Absci's generative AI platform.

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025.

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201, offers potential upside but increases burn rates and development risks. Strategic partnerships, like those with AMD and AstraZeneca, validate Absci's platform but have yet to generate significant revenue.

Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market

Which Healthcare Stock Is the Best Buy Right Now?

In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success with a new product—or even clinical trial results suggesting a new product could be on the horizon—they can experience huge rallies in a very short period of time.

Which Healthcare Stock Is the Best Buy Right Now?

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

Absci to Participate in Upcoming Investor Conferences

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

See News Rankings

Charts implemented using Lightweight Charts™